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Abstract
Background: In certain diseases clinical experts may judge that the intervention with the best prospects is the
addition of two treatments to the standard of care. This can either be tested with a simple randomized trial of
combination versus standard treatment or with a 2 × 2 factorial design.
Methods: We compared the two approaches using the design of a new trial in tuberculous meningitis as an
example. In that trial the combination of 2 drugs added to standard treatment is assumed to reduce the hazard of
death by 30% and the sample size of the combination trial to achieve 80% power is 750 patients. We calculated
the power of corresponding factorial designs with one- to sixteen-fold the sample size of the combination trial
depending on the contribution of each individual drug to the combination treatment effect and the strength of
an interaction between the two.
Results: In the absence of an interaction, an eight-fold increase in sample size for the factorial design as compared
to the combination trial is required to get 80% power to jointly detect effects of both drugs if the contribution of
the less potent treatment to the total effect is at least 35%. An eight-fold sample size increase also provides a
power of 76% to detect a qualitative interaction at the one-sided 10% significance level if the individual effects of
both drugs are equal. Factorial designs with a lower sample size have a high chance to be underpowered, to show
significance of only one drug even if both are equally effective, and to miss important interactions.
Conclusions: Pragmatic combination trials of multiple interventions versus standard therapy are valuable in
diseases with a limited patient pool if all interventions test the same treatment concept, it is considered likely that
either both or none of the individual interventions are effective, and only moderate drug interactions are
suspected. An adequately powered 2 × 2 factorial design to detect effects of individual drugs would require at
least 8-fold the sample size of the combination trial.
Trial registration: Current Controlled Trials ISRCTN61649292
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Tuberculous meningitis (TBM) is the most severe form
of M. tuberculosis infection, and kills or disables more
than half of those affected [1]. Effective new intervention
strategies are thus urgently needed. The study hypoth-
esis of a new randomized clinical trial whose protocol is
published along with the current manuscript [2] is that
current anti-mycobacterial regimes are not potent
enough and that increasing the levels of effective anti-
mycobacterial drugs in the cerebrospinal fluid will
i m p r o v ec l i n i c a lo u t c o m e .T h i sh y p o t h e s i si st e s t e db y
simultaneously increasing the dose of rifampicin and
adding levofloxacin to the standard treatment and per-
forming a two-group comparison of intensified versus
standard treatment. This approach allows testing of the
primary study hypothesis but it does not allow quantifi-
cation of the individual effects of each drug or facilitate
exploration of potential synergistic or antagonistic inter-
actions between them.
A 2 × 2 factorial design would potentially answer
these questions by simultaneously randomizing patients
to one of two levels of factor 1 (e.g. standard treatment
vs. standard treatment + treatment A [intensified rifam-
picin]) and to one of two levels of factor 2 (e.g. standard
treatment vs. standard treatment + treatment B [levo-
floxacin]) such that one quarter of the patients receive
each of the possible combination treatments. A typical
analysis of factorial designs estimates the overall treat-
ment effect of treatment A by pooling across levels of
factor 2, i.e. the estimate corresponds to the average of
the treatment effects of treatment A in patients rando-
mized to standard treatment for factor 2 and those ran-
domized to treatment B for factor 2, respectively.
Crucially, all randomized patients are included in the
estimation of the effect of treatment A and, thus, a 2 ×
2 factorial design has essentially the same power as a
corresponding simple randomized trial which would
only randomize factor 1. Factorial designs thus have the
potential to answer two (or multiple) questions for the
“price” of one and appear to be ideal designs for evaluat-
ing combination treatments.
One major complication of studying combination treat-
ments is that they may interact, i.e. that the effect of
treatment A is different depending on whether it is
added to standard treatment or standard treatment
+treatment B (or, equivalently, that the effect of adding
both treatments A and B is not equal to the sum of their
individual effects). Both synergistic and antagonistic
(negative) interactions are possible. While interactions
can be studied in the framework of factorial designs, they
complicate their analysis and interpretation. In particular,
the interpretation of the treatment effect estimate from
the standard analysis outlined above is problematic [3-6].
The need to improve outcomes in diseases with high
morbidities and mortalities is clear. In rare diseases,
such as TBM, the pace of progress is slowed because of
the time needed to recruit sufficient numbers of patients
to studies powered to appropriate clinical endpoints.
Clinical experts may judge that the intervention with
the best prospects to improve outcomes is the addition
of a combination of several drugs to the standard of
care. This new intervention could either be tested with
a simple randomized trial of combination therapy versus
standard of care or with a factorial design which evalu-
ates each intervention component separately. The objec-
tive of the present manuscript is to compare these
approaches in terms of their statistical power using our
study in TBM as a representative example. We find that
in certain situations performing the pragmatic combina-
tion trial is the preferred approach.
Methods
Sample size calculation for the new TBM trial
The primary endpoint of our proposed study in TBM is
overall survival during a follow-up period of 9 months.
We expect a 9-month mortality rate of approximately
40% in the control arm and an absolute risk reduction
of 10% (from 40% to 30%) due to intensified combina-
tion treatment was judged as both realistic and clinically
relevant. Assuming proportional hazards, these mortality
estimates translate into a hazard ratio of 0.7 [= log(1-
0.3)/log(1-0.4)], i.e. a 30% risk reduction due to intensi-
fied treatment on the hazard ratio scale. Using Schoen-
feld’s formula [7], a total of 247 deaths are required to
detect a hazard ratio of 0.7 based on a two-sided test at
the 5% significance level with 80% power; assuming an
overall mortality rate of 35% in the trial, this translates
into a need to enroll 706 patients. In order to account
for potential deviations from our assumptions and losses
to follow-up, a safety margin of 6% was added to this
number leading to a total sample size of 750 patients
(375 per treatment group). Further details of the sample
size calculation are described in the study protocol [2].
Factorial designs without interactions
We first assumed that the combination treatment effect is
as described above, i.e. that the hazard ratio of combina-
tion treatment versus control is 0.7, and that there is no
interaction present, i.e. that the total combination treat-
ment effect (as measured on the log-hazard ratio scale) is
equal to the sum of the individual contributions of treat-
ment A [intensified rifampicin] and B [levofloxacin].
For our investigations we varied the total sample size
of a hypothetical factorial trial from the size of the two-
group trial (i.e. 750 patients) to 8-fold its size (i.e. 6’000
patients) and assumed that the total observed number
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sample size calculation above). In addition, we varied
the contribution of the more potent of the two indivi-
dual treatments to the combination treatment effect
f r o m5 0 - 1 0 0 % .T h ea n a l y s i sw a sa s s u m e dt ob eaC o x
regression analysis with treatment indicators for each
treatment as covariates. We then calculated the statisti-
cal power of the following comparisons of the factorial
design:
- Probability that the two tests for the effects of indivi-
dual treatment A and B both reach statistical
significance.
- Probability that the test of the more potent of the
two treatments reaches statistical significance.
- Probability that at least one of the two tests for indi-
vidual treatment A and B effects reaches statistical
significance.
- Probability that the comparison of combination
treatment versus standard of care reaches statistical sig-
nificance in the factorial design.
- Power of a two-arm trial of combination treatment
versus standard of care with the same sample size as the
factorial design.
Details regarding the power calculation are provided
in Additional file 1: appendix. Of note, the formulas in
the appendix are approximations. In addition, we per-
formed a simulation study where we estimated exact
power based on results from Cox regression analyses of
simulated trial data assuming exponentially distributed
survival times and averaging results over 10’000 simu-
lated trials for each parameter setting. As results from
this simulation study were qualitatively identical to the
approximations, the simulation results are not reported
here.
Factorial designs with interactions
In a second step, we investigated the impact of interac-
tions assuming that the effect of either treatment A or B
alone leads to a reduction in the hazard of 0.84, i.e.
identical effects of each drug alone and a combination
treatment effect corresponding to a hazard ratio of 0.84
0.84 = 0.7 in the absence of an interaction. For our
investigations we varied the total sample size of a
hypothetical factorial trial from 4-fold the size of the
two-group trial (i.e. 3’000 patients) to 16-fold its size
(i.e. 12’000 patients) and varied the strength of the inter-
action effect from -200% to + 200% of the effect of
either drug alone. An interaction of -200% corresponds
to an effect of combination treatment of zero, i.e. the
effect of either drug vanishes when combined with the
other, an interaction of size -100% indicates that either
drug alone works as well as their combination, whereas
an interaction of +200% corresponds to a strongly
synergistic interaction where the combination treatment
effect is twice the sum of the individual effects of A and
B alone. The analysis was assumed to be a Cox regres-
sion analysis with treatment indicators for each therapy
as covariates plus an interaction term. For each scenario,
we calculated the power of the following comparisons:
- Probability that the interaction test reaches statistical
significance and probability that the one-sided p-value is
≤ 10% (indicating mild evidence for an interaction).
- Probability that the main effect corresponding to
treatment A reaches statistical significance.
- Power of a two-arm trial of combination treatment
versus standard of care with the same sample size as the
factorial design.
Of note, the main effect of treatment A corresponds
to an averaged effect of treatment A when added to
either standard of care or standard of care plus treat-
ment B and may be difficult to interpret clinically.
Other conventions and statistical software
Statistical significance was determined as significance at
the one-sided 2.5% significance level. We used one-sided
tests in the direction of the true (simulated) effect
throughout because power formulas are simpler for the
connected rejection areas of one-sided tests. No adjust-
ment for multiple testing was performed. All calcula-
tions were performed with the statistical software R
version 2.9.1 [8].
Results
Power curves for the factorial design assuming no statis-
tical interactions depending on the sample size and the
contribution of the more potent individual treatment are
displayed in Figure 1. It is apparent from these curves
that if only one drug contributes to the total treatment
effect, the power of the factorial design to detect indivi-
dual treatment effects is essentially equal to the power of
the combination treatment trial to detect the combina-
tion effect. However, if both drugs contribute to the total
effect, power is much diminished. For example, the right
lower panel of Figure 1 shows that in order to get 80%
power to detect an effect for both individual treatments
simultaneously assuming the split-up in effects between
the two drugs is between 35:65 to 65:35, one would need
an 8-fold increased sample size. Moreover, the figure
shows that a factorial trial with suboptimal sample size
has a much higher chance of concluding that one of the
treatment works than concluding that both jointly work,
i.e. that the combination treatment is the optimal treat-
ment, even if both treatments have similar effects. For
example, with 1’500 patients and equal effects of both
individual treatments, the probability that exactly one of
them is significant is 2-times higher than the probability
that both jointly reach statistical significance (chances of
approximately 50% vs. 25%). Finally, for the comparison
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requires twice the sample size of the combination trial
for equal power (ignoring multiple testing issues for the
factorial design).
Power curves for the factorial design assuming equal
individual treatment effects plus an interaction depend-
ing on the sample size and the strength of the interaction
are displayed in Figure 2. The curves show that the
power of the main effect of the trial is strongly reduced
in the presence of a negative interaction. Further, in
order to detect an interaction of -100%, i.e. that the effect
of combination treatment is equal to either drug alone,
with 80% power, one would need 16-fold the sample size
of the two-group combination trial. With an 8-fold sam-
ple size and a liberal one-sided significance level of 10%,
power to detect an interaction of this size would be 76%.
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Figure 1 Power curves for 2 × 2 factorial designs without an interaction assuming a hazard ratio of combination treatment versus
standard treatment of 0.7 and an overall mortality of 35%. Figure legend text: The black, dashed blue, and red lines correspond to the
probability that the more potent individual treatment, at least one of the two treatments or both treatments jointly, respectively, reach statistical
significance. The orange and green lines correspond to the probability of a significant difference between combination treatment and standard
treatment in the factorial trial and in a 2-group trial of combination treatment versus standard treatment with equal sample size, respectively.
Wolbers et al. Trials 2011, 12:26
http://www.trialsjournal.com/content/12/1/26
Page 4 of 7Discussion
We found that a 2 × 2 factorial design powered to
detect individual treatment effects would require at least
8-fold the sample size of a two-group combination treat-
ment trial based on the same assumptions. This increase
in sample size would guarantee sufficient power to
detect both individual treatment effects assuming that
the contribution of each individual treatment to the
joint effect is at least 35% and that there are no interac-
tions. Moreover, at least an 8-fold increased sample size
is required to detect at least mild evidence for a qualita-
tive interaction of -100%, i.e. that either treatment alone
has the same effect as the combination. The reasons for
this high price for separating out combination effects
come from two main sources: First, if there is no inter-
action and both drugs have equal contributions to the
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Figure 2 Power curves for 2 × 2 factorial designs with an interaction assuming equal individual contributions from both treatments
corresponding to hazard ratios of 0.84 and an overall mortality of 35%. Figure legend text: The blue lines correspond to the power of the
interaction test (solid line: one-sided 2.5% significance level, dashed line: one-sided 10% significance level), the black line to the power of the
main effect for treatment A, and the green line to the power of a 2-group trial of combination treatment versus standard treatment with equal
sample size.
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combination effect which requires 4-fold the sample size
to detect individually (and more than 5-fold the original
sample size to detect both jointly with 80% power). A
further increase in sample size is mandated to protect
against the possibility of unequal contributions of the
two drugs. Second, it is well-known that interaction
tests lack power, i.e. in order to detect an interaction of
the same size as a main effect with equal power, 4-fold
the sample size is required [3]. Moreover, modest nega-
tive interactions can considerably diminish the power to
detect treatment effects in the factorial design even in
cases that have little power to detect this interaction [4].
An 8-fold sample size increase, i.e. 6’000 patients in
total, would transform our study protocol from what
will be the largest trial ever conducted in TBM to an
impossible study. Thus, a factorial design would have to
make much more aggressive assumptions regarding the
individual treatment effects in order to arrive at a more
realistic sample size. However, such assumptions would
lead to an increased likelihood that the trial is under-
powered. Even if either of the two intervention effects
reaches significance in such an underpowered study, we
have shown that chances are high that substantial inter-
action effects are not discovered and that only one of
the treatments reaches statistical significance even if
both are equally effective. An earlier publication showed
that typical analysis strategies in factorial designs have a
relatively low chance of finding the optimal treatment
combination in many situations [5] and these chances
are even more diminished if the trial does not even have
sufficient power to detect the individual treatment
effects.
Based on these findings, we believe that a pragmatic
two arm trial of combination therapy versus standard
treatment is the design of choice under the following
assumptions: First, an adequately powered factorial
design which allows separating out individual treatment
effects is not feasible due to excessive sample size. Sec-
ond, both interventions test the same broad study
hypothesis and the combination is considered most pro-
mising. Third, it is considered likely that either both or
neither of the two drugs are effective and at most mod-
erate interactions between the two interventions are
expected. As we have seen, in case only one of the two
interventions is efficacious and there is no interaction, a
factorial trial would be optimal and could indeed deliver
two answers for the price of one. Factorial designs and,
more generally, fractional factorial designs are very effi-
cient designs to screen several potential interventions
many of which are likely inefficacious [9]. Fourth,
neither of the two interventions has substantially higher
costs or is expected to be much more toxic than the
other. Finally, a pragmatic combination trial is unlikely
to be acceptable for regulatory drug approval which
requires proof of efficacy for each individual component.
Our proposed trial in TBM fulfils all of the above con-
ditions. TBM is a relatively rare disease with a limited
number of patients globally, but devastating for those
who are affected. Both interventions in our TBM trial
test the same broad study hypothesis, i.e. that increasing
levels of effective anti-mycobacterial drugs in the cere-
brospinal fluid will improve treatment outcome. If this
trial is successful, it will likely lead to follow-up trials
which may further optimize the anti-tuberculosis treat-
ment. This optimization may be based on the new drugs
which are currently under development, e.g. TMC207 or
PA824. One could in principle also revisit the question
whether both components of the intensified treatment
are necessary, perhaps based on a 3-arm non-inferiority
trial of individual interventions versus combination ther-
apy. However, such a series of simple (superiority and
non-inferiority) trials would likely be less efficient than
one large factorial trial. If the combination trial is not
successful, follow-up trials may focus on new study
hypotheses. For example, it could be that drugs which
prevent or reduce the risk of infarction result in lower
mortality and better outcome for TBM patients [10].
Our main interest in the factorial design is that it
allows separating out individual treatment effects and
investigation of interactions. An alternative would be to
perform the same trial but analyze it as a 4-arm trial
instead which focuses on the comparison of each inter-
vention and combination treatment, respectively, to the
standard treatment. As we saw, such a trial would only
require 2-fold the sample size of the combination trial
to detect a combination effect if no adjustment for mul-
tiplicity is performed (and 2.7-fold the sample size using
a Bonferroni correction). In addition, such a trial could
be adaptive, i.e. allow for intermediate dropping of inef-
ficacious arms [11]. However, such an analysis would
not exploit the factorial design and have very low power
to detect individual treatment effects. Other alternative
designs might also be considered. Options would
include 3-arm trials of the standard treatment versus
the two most promising combinations or to first initiate
ap i l o ts t u d yt of u r t h e ra s s e s st h es a f e t ya n dp h a r m a c o -
logical profile of both interventions and their interac-
tion. However, none of these trials can avoid the
fundamental problem that the cost of separating out
combination treatment effects into their components
may be prohibitively high.
Conclusions
Pragmatic combination trials of multiple interventions
versus standard therapy are valuable in diseases with a
limited patient pool if all interventions test the same
treatment concept, if it is considered likely that a
Wolbers et al. Trials 2011, 12:26
http://www.trialsjournal.com/content/12/1/26
Page 6 of 7combination effect is based on contributions from all
individual interventions, and only moderate (negative or
positive) treatment interactions are suspected. In the
case of two interventions, a 2 × 2 factorial design which
is adequately powered to detect individual treatment
e f f e c t sw o u l dr e q u i r ea tl e a s t8 - f o l dt h es a m p l es i z eo f
the combination trial.
Additional material
Additional file 1: Technical appendix. Power calculation for 2 × 2
factorial trials.
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